HAIFA, Israel--(BUSINESS WIRE)--May 8, 2006--Pluristem Life Systems, Inc. (OTCBB:PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, today announced that a patent application has been filed with the US Patent and Trademark Office for its stem cell therapy product known as PLX-1. PLX-1 is intended to offer a breakthrough solution to improved engraftment during bone marrow transplant procedures that use umbilical cord blood (UCB).
